Five patent applications. One arXiv preprint. Three papers in preparation. The IP foundation under the structure-centric paradigm is being built deliberately, with priority dates established before public disclosure of implementation details.
| Title | Status | Filing |
|---|---|---|
| AdaBox — structure-centric clustering algorithm and scale-invariant parameter formulation | Filed | January 2026 |
| SCOPE — decomposable evaluation framework for density-based clustering | Filed | January 2026 |
| AdaGraph — native high-dimensional clustering, including SLCD pipeline, Density-Aware Sampler, two-pass prototype deployment, and subspace probe (six independent claims plus 22 dependent) | Prepared, with counsel | April 2026 |
| Graph-SCOPE — unsupervised decomposable validity metric for high-dimensional clustering | Prepared, with counsel | April–May 2026 |
The AdaGraph filing alone protects six distinct inventive concepts as independent claims: the core AdaGraph algorithm, the scale-invariant parameter formulation, the Density-Aware Sampler, the two-pass prototype deployment method, the subspace probe for automatic dimensionality assessment, and the complete SLCD pipeline. Each is independently licensable.
Structure-Centric Density-Based Clustering with Scale-Invariant Parameters
A reduced preprint establishing priority for the structure-centric paradigm and the scale-invariant parameter formulation. Includes the foundational AdaBox algorithm and the SCOPE evaluation framework. Implementation details are deliberately abbreviated to establish priority without enabling immediate replication.
Full algorithmic specification, complexity analysis, theoretical guarantees, and empirical validation across text, genomics, and materials science. Target venue: KDD 2026.
Mathematical formulation of the five-component decomposition; benchmark against Silhouette, Davies-Bouldin, Calinski-Harabasz across 10 synthetic and 5 real-world datasets; dimensionality scaling proof. Target venue: NeurIPS 2026.
The C6 module discovery on GSE31210, literature validation of all 44 genes, and laboratory validation of the highest-priority candidates. Co-authored with cancer genomics laboratory. Target venue: a leading genomics or oncology journal.
Algorithmic IP is notoriously difficult to enforce after public disclosure. The structure-centric portfolio addresses this by separating the priority-establishment phase (arXiv preprints with reduced implementation detail) from the full publication phase (peer-reviewed papers after patent filing is complete). Patent priority dates precede every full disclosure.
This sequencing is also why the research roadmap matters: a published paper demonstrating AdaGraph's discovery of cancer-relevant gene modules is worth more — both academically and commercially — than a paper announcing the algorithm in isolation. Each domain validation strengthens both the academic record and the commercial case.